Toll Free: 1-888-928-9744

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2016

Published: Jun 22, 2016 | Pages: 81 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2016', provides in depth analysis on Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted pipeline therapeutics. 

The report provides comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
- The report reviews Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) Overview 7 Therapeutics Development 8 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Products under Development by Stage of Development 8 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Products under Development by Therapy Area 9 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Products under Development by Indication 10 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Products under Development by Companies 14 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Products under Development by Universities/Institutes 16 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Assessment 18 Assessment by Monotherapy/Combination Products 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Companies Involved in Therapeutics Development 25 Aduro BioTech, Inc. 25 Amgen Inc. 26 BriaCell Therapeutics Corp. 27 GlaxoSmithKline Plc 28 Humabs BioMed SA 29 KaloBios Pharmaceuticals, Inc. 30 Morphotek, Inc. 31 Sillajen Biotherapeutics 32 Takeda Pharmaceutical Company Limited 33 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Drug Profiles 34 GSK-3196165 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 lenzilumab - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 MORAb-022 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 namilumab - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 pexastimogene devacirepvec - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 STINGVAX - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 SVBR-1GM - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 talimogene laherparepvec - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Dormant Projects 65 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Discontinued Products 68 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Featured News & Press Releases 69 May 31, 2016: Transgene Announces Poster Presentation at ASCO Annual Meeting on the Phase 3 PHOCUS Clinical Trial with Pexa-Vec Oncolytic Immunotherapy 69 May 18, 2016: Amgen To Present Data on IMLYGIC (talimogene laherparepvec) At ASCO 2016 69 May 18, 2016: BriaCell Appoints Contract Research Organization, Cancer Insight, to Manage Its Upcoming Phase I/IIa Clinical Trials in Advanced Breast Cancer 70 May 16, 2016: SillaJen Announces Commercial Manufacturing Agreement with ABL Europe For Lead Oncolytic Virus, Pexa-Vec 71 Apr 18, 2016: GSK announces start of a phase II study to evaluate an anti GM-CSF antibody for inflammatory hand osteoarthritis 71 Apr 12, 2016: BriaCell Files a Patent Application to Protect Additional Cancer Vaccines With Genetic Features Thought to Promote Strong Anti-Tumor Activity 72 Apr 05, 2016: BriaCell Targeting Launch of Its Phase I/II Clinical Trial During Current Quarter 73 Mar 29, 2016: SillaJen Enrolls First U.S. Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer 73 Mar 29, 2016: BriaCell Discovers Gene Signature of BriaVax Cancer Vaccine Consistent With Exceptional Efficacy in Clinical Trial 74 Mar 16, 2016: NICE consults on 'no' recommendation for skin cancer drug talimogene laherparepvec 75 Jan 05, 2016: SillaJen Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer 76 Dec 20, 2015: Moffitt Cancer Center And UC Davis Suspends Clinical Trial Of KaloBios' Leukemia Drug 77 Dec 17, 2015: European Commission Approves Amgen's IMLYGIC (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe 77 Dec 07, 2015: Morphotek Announces Phase 1 Results From MORAb-022-001 Trial in Healthy Subjects and Patients with Mild-to-Moderate Rheumatoid Arthritis 78 Nov 16, 2015: Amgen to Present IMLYGIC (Talimogene Laherparepvec) Data at the 2015 International Congress of the Society for Melanoma Research 79 Appendix 80 Methodology 80 Coverage 80 Secondary Research 80 Primary Research 80 Expert Panel Validation 80 Contact Us 80 Disclaimer 81
List of Tables
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Early Stage Products, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Products under Development by Companies, H1 2016 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Assessment by Monotherapy/Combination Products, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 20 Number of Products by Stage and Route of Administration, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 24 Pipeline by Aduro BioTech, Inc., H1 2016 25 Pipeline by Amgen Inc., H1 2016 26 Pipeline by BriaCell Therapeutics Corp., H1 2016 27 Pipeline by GlaxoSmithKline Plc, H1 2016 28 Pipeline by Humabs BioMed SA, H1 2016 29 Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 30 Pipeline by Morphotek, Inc., H1 2016 31 Pipeline by Sillajen Biotherapeutics, H1 2016 32 Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 33 Dormant Projects, H1 2016 65 Dormant Projects (Contd..1), H1 2016 66 Dormant Projects (Contd..2), H1 2016 67 Discontinued Products, H1 2016 68


List of Figures
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Early Stage Products, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 18 Number of Products by Mechanism of Actions, H1 2016 19 Number of Products by Stage and Mechanism of Actions, H1 2016 19 Number of Products by Routes of Administration, H1 2016 21 Number of Products by Stage and Routes of Administration, H1 2016 21 Number of Products by Molecule Types, H1 2016 23 Number of Products by Stage and Molecule Type, H1 2016 23

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the marke

Read More...

Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expe

Read More...

Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to dri

Read More...

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...

Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growi

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify